.Net Biotechnology Programming 
GeekWire
AUGUST 2, 2024
Sana Biotechnology CEO Steve Harr cuts the ribbon at the company’s new manufacturing facility in Bothell, Wash., The Bothell facility will house Sana’s proprietary cancer drug program. The diabetes program involves turning stem cells into insulin-producing islet cells. The company’s net losses grew to $107.5
GeekWire
MARCH 8, 2022
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We million in 2020.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeekWire
JUNE 30, 2021
The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Net losses were $14.4 2020 revenue was $4.7 million, up from $2 million for 2019. 2020 revenue was $4.7 million, up from $2 million for 2019.
CTOvision
FEBRUARY 10, 2016
The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.
GeekWire
JUNE 24, 2020
million net loss and $132.5 million net loss and $94.8 Accolade would be the first Seattle-area company to go public since Adaptive Biotechnologies last year. It plans to trade on the Nasdaq exchange under the ticker ACCD. The company’s latest S-1 registration filing shows a $51.3 That’s compared to a $56.5
GeekWire
OCTOBER 9, 2024
Other former positions include leadership roles at the Gates Foundation and directing the global drug development program at PATH. Susan Wyrick of Sana Biotechnology. “It’s been a wonderful ride launching and leading this deep-tech startup mentorship program in Seattle for just over 3 years now.
GeekWire
DECEMBER 27, 2022
He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. Earlier companies are considering fewer development programs and having a slower ramp on hiring. Neoleukin Therapeutics recently shed staff in the wake of disappointing clinical data for its lead program, for example.
Expert insights. Personalized for you.
117 
Let's personalize your content